- Home
- MDIA vs DBVT Comparison
MDIA vs DBVT Comparison
Compare MDIA & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDIA
- DBVT
- Stock Information
- Founded
- MDIA 2019
- DBVT 2002
- Country
- MDIA United States
- DBVT France
- Employees
- MDIA N/A
- DBVT N/A
- Industry
- MDIA Broadcasting
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDIA Consumer Discretionary
- DBVT Health Care
- Exchange
- MDIA Nasdaq
- DBVT Nasdaq
- Market Cap
- MDIA 59.3M
- DBVT 67.8M
- IPO Year
- MDIA N/A
- DBVT N/A
- Fundamental
- Price
- MDIA $1.08
- DBVT $0.59
- Analyst Decision
- MDIA
- DBVT Strong Buy
- Analyst Count
- MDIA 0
- DBVT 2
- Target Price
- MDIA N/A
- DBVT $6.00
- AVG Volume (30 Days)
- MDIA 57.4K
- DBVT 2.0M
- Earning Date
- MDIA 11-26-2024
- DBVT 11-06-2024
- Dividend Yield
- MDIA N/A
- DBVT N/A
- EPS Growth
- MDIA N/A
- DBVT N/A
- EPS
- MDIA N/A
- DBVT N/A
- Revenue
- MDIA $69,296,000.00
- DBVT $12,515,000.00
- Revenue This Year
- MDIA N/A
- DBVT N/A
- Revenue Next Year
- MDIA N/A
- DBVT $2,860.00
- P/E Ratio
- MDIA N/A
- DBVT N/A
- Revenue Growth
- MDIA 94.96
- DBVT 125.54
- 52 Week Low
- MDIA $0.40
- DBVT $0.50
- 52 Week High
- MDIA $6.86
- DBVT $2.14
- Technical
- Relative Strength Index (RSI)
- MDIA 34.76
- DBVT 34.55
- Support Level
- MDIA $1.11
- DBVT $0.56
- Resistance Level
- MDIA $1.34
- DBVT $0.81
- Average True Range (ATR)
- MDIA 0.11
- DBVT 0.05
- MACD
- MDIA 0.00
- DBVT -0.02
- Stochastic Oscillator
- MDIA 3.23
- DBVT 10.42
About MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales and events including sponsorships and ticket sales, licensing, and syndication.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.